Diffuse large B-cell lymphoma
Conditions
Interventions
Experimental group:O-R-CHOP regimen
Sponsors
The First Affiliated Hospital of Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1)Double expression of diffuse large B cell lymphoma must be confirmed before enrollment.Diagnostic criteria refer to 2016 WHO subtyping (MYC> 40%, BCL2> 50%). 2) Age 18-70 years; 3) Eastern Oncology (ECOG) fitness score 0-2; 4) subjects must have good organ function; 5) fertile female subjects must use efficient contraception before and during the beginning of the first study administration, until 3 months after the last dose of obrutinib and CHOP, or 12 1)months after the last dose of rituximab, whichever is older.Male subjects were eligible if the vas were removed or if they agreed to combine barrier contraception and other methods during the study period and 3 months after the last administration of the CHOP regimen, or 12 months after the last rituximab administration).7) Life expectancy of 6 months; 8) Voluntary informed consent, leading to understanding and compliance with the study requirements.
Exclusion criteria
Exclusion criteria: 1) Previous systemic treatment with DLBCL 2) Currently with clinically significant active cardiovascular disease such as uncontrolled arrhythmia, uncontrolled hypertension, congestive heart failure, any grade 3 or 4 heart disease determined by the New York Cardiology Association (NYHA) functional classification, or a history of myocardial infarction within 6 months before screening; 3) known human immunodeficiency virus (HIV) infection; 4) pregnant or lactating women; 5) unable to understand, follow the study protocol or sign informed consent;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Event-free survival ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival;Overall Survival;Complete response;Safety;Objective response rate; | — |
Countries
China
Contacts
Public ContactZhen Cai
The First Affiliated Hospital of Zhejiang University School of Medicine
Outcome results
None listed